EGFR and non-small cell lung carcinoma: For the convenience of this study, NSCLC was broadly divided into two groups: one for patients with EGFR mutations and the other for patients with wildtype EGFR. The second group is an oversimplification and includes a gamut of different mutations including some driver mutations such as KRAS.